Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Articles online first > Minerva Gastroenterologica e Dietologica 2020 Dec 03

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Gastroenterologica e Dietologica 2020 Dec 03

DOI: 10.23736/S1121-421X.20.02780-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Eosinophilic esophagitis and biologics

Matteo GHISA 1 , Giorgio LASERRA 1, Daria MANIERO 1, Elisa MARABOTTO 2, Brigida BARBERIO 1, Filippo PELIZZARO 1, Ilenia BARBUSCIO 3, Fabiana ZINGONE 1, Vincenzo SAVARINO 2, Edoardo SAVARINO 2

1 Department of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, Padova, Italy; 2 Department of Internal Medicine, Gastroenterology Unit, University of Genoa, Genoa, Italy; 3 Gastroenterology Unit, San Bortolo Hospital, Azienda ULSS n.8 Berica, Vicenza, Italy


PDF


EoE incidence and prevalence have sharply increased in the last decade and management of these patients is changing rapidly. Standard regimens as elimination diet, proton pump inhibitors and topical swallowed steroids are not able to achieve remission in all patients. Moreover, loss of efficacy and safety concerns for long-term medical treatments are rising questions. As for other chronic immune-mediated diseases, biologics have been evaluated for treatment of EoE. Several targets in the Th2-mediated inflammatory cascade with eosinophilic mucosal infiltration, have been tested with alternating results. This review provides a comprehensive discussion of the available studies evaluating biologics in EoE and the possible future options most desirable for these patients.


KEY WORDS: Eosinophilic esophagitis; Biologics; Dupilumab; Benralizumab; treatment

inizio pagina